Divi’s Labs Q4 results: net profit up 67% to Rs 538 crore, Rs 30 dividend declared

Incorporated in October 1990, Divi’s Laboratories is pharmaceutical and Biotechnology company engaged in Generic API, Custom Synthesis and Nutraceuticals.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Indian pharma major Divi’s Laboratories Ltd on May 25 reported a 67 percent rise in consolidated net profit to Rs 538 crore in the Jan-March quarter of FY24 from Rs 321 crore in the same period a year ago.

Revenue for the quarter grew 18 percent from last year to Rs 2,303 crore. It was Rs 1,951 crore in the same period a year ago.

The Board also recommended a final dividend of Rs 30/- (i.e. 1,500 percent) per equity share of face value Rs 2/- each for the financial year 2023-24, subject to approval of the members at the ensuing 34th Annual General Meeting (AGM).

EBITDA or Earnings Before Interest, Tax, Depreciation and Amortisation increased to  Rs 731 crore from Rs 473 crore in the same period a year ago. EBITDA margin for the quarter though, expanded to 31.7 percent from  25 percent YoY.

Incorporated in October 1990, Divi’s Laboratories is pharmaceutical and Biotechnology company engaged in Generic API, Custom Synthesis and Nutraceuticals. It is promoted by Dr Murli K. Divi. Divi’s has global leadership position in CRAMS and Generic APIs. It is catering to therapeutic segments like Cardiovascular, Anti-Inflammatory, anti-cancer and Central nervous system drugs.